Skip to main content
CVM logo

CEL-SCI Corporation (CVM) Stock Price & Analysis

CEL-SCI Corporation (CVM) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $1.47 (+6.52%), as of the Nov 19, 2026 trading session; market cap $25.9M.

Educational signal · not a buy or sell recommendation · How to read this

$1.47 +$0.09 (+6.52%) Market Cap $25.9M

CEL-SCI Corporation · CVM · AMEX

CEL-SCI Corporation is a biotechnology company focused on researching and developing immunotherapies for cancer and infectious diseases. Their lead investigational immunotherapy, Multikine, is currently in Phase III clinical trials for head and neck cancer treatment.

Price as of Nov 19, 2026

Key Statistics

29 of 100

MoonshotScore v2 · CEL-SCI (CVM)

Weak
Business Quality Thin (26)
Financial Safety Fragile (4)
Valuation Bubble (6)
Growth Durability Flat (42)
Momentum Quiet (49)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a fragile balance sheet and an expensive valuation, though growth is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 0 of the last 8 reports
  • Altman Z -37.89 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, a rich price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CVM (57 recorded, newest six shown)
RecordedScoreBand
27Weak
27Weak
28Weak
28Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.47
Change on the day+6.52%
Market capitalisation$25.9M—
Shares traded on the day263.4K

Price & events

Other perspectives

Council score for CEL-SCI (CVM): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Negative
Growth Durability Neutral
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 5, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Weak
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is CEL-SCI (CVM), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CEL-SCI Corporation (CVM) is listed on AMEX. The market values it at $25.9M.

2 · Latest results

What do the latest results show for CEL-SCI (CVM)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for CEL-SCI (CVM)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, a rich price. The distress and quality screens read Altman Z -37.89 · Piotroski F 2. Trailing ratios: ROA -66.8% · current ratio 1.48.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -37.89 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at CEL-SCI (CVM)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $4.69M · EPS -3.07 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for CVM.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does CEL-SCI compare with its peers?

Short answer

CEL-SCI's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Named competitor$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
Pfizer Inc. (PFE) Named competitor$28.06 Nov 18, 2026$160B67 5-pillar Nov 18, 2026
CEL-SCI (CVM) — this page$1.47$25.9M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$4.69M
EPS estimate
$-3.07

Measured against a quoted price of $1.47 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CVM in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CVM in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: CVM Stock

These answers are editorial: 1 of these 9 answers is drawn from the CVM research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CVM?

CVM carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. CEL-SCI Corporation is a biotechnology company focused on researching and developing immunotherapies for cancer and infectious diseases.

Is CVM a good stock to buy?

Stock Expert AI does not rate CVM buy, sell or hold. CEL-SCI Corporation carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CVM stock price today?

The last price recorded for CEL-SCI Corporation (CVM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about CVM stock?

Analyst coverage of CEL-SCI Corporation (CVM) is limited, reflecting the company's small market capitalization and early stage of development. The stock's valuation is highly dependent on the outcome of the Multikine Phase III clinical trial. Positive trial results could lead to a significant increase in the stock price, while negative results could have the opposite effect.

What are the key factors to evaluate for CVM?

CEL-SCI Corporation (CVM) holds a MoonshotScore in the low range. Multikine is in Phase III clinical trials for head and neck cancer, representing a potential near-term catalyst. Not financial advice.

How frequently does CVM data refresh on this page?

CVM's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CVM's recent stock price performance?

CEL-SCI Corporation (CVM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary LEAPS technology platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CVM overvalued or undervalued right now?

CEL-SCI Corporation (CVM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CVM before investing?

Before investing in CEL-SCI Corporation (CVM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 4 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.